Every 424B that Lakewood-Amedex Biotherapeutics Inc. (LABT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LABT filings page.
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotech developing antimicrobial therapies, led by Nu-3 for infected diabetic foot ulcers. For the six months ended June 30, 2026, it reported a net loss of $4.7 million, wider than $1.2 million a year earlier, as research and development expenses rose to $0.7 million and general and administrative expenses to $4.0 million, driven largely by public-company and advisory costs.
The company strengthened its balance sheet through a private placement of 937,500 Series C preferred shares, with $7.5 million gross and approximately $6.8 million net proceeds, and by converting $1.5 million of convertible notes and all Series A and B preferred (including dividends) into common stock. At June 30, 2026, cash and cash equivalents were $2.6 million, short-term certificates of deposit were $2.0 million, and working capital was about $4.2 million.
Despite this recapitalization, management states that recurring losses and expected cash use raise substantial doubt about continuing as a going concern within one year of issuance, as additional financing will be required beyond early 2027. Management also concludes disclosure controls were not effective due to material weaknesses in internal control over financial reporting.
Lakewood-Amedex Biotherapeutics Inc. implemented a 1-for-10 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on June 19, 2026. The company said shares will trade on a split-adjusted basis when Nasdaq opens on June 22, 2026 and that fractional shares will be rounded up.
The Certificate of Change also reduces the company’s authorized common shares to 12,500,000 and the company’s Nasdaq symbol remains LABT; the security has a new CUSIP 51255A201.
Lakewood-Amedex Biotherapeutics Inc. adopted a 1-for-10 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on June 19, 2026, with trading on a split-adjusted basis beginning when Nasdaq opens on June 22, 2026. The company will proportionately adjust outstanding equity awards, preferred stock, warrants and plan issuances, and will reduce authorized common shares to 12,500,000 after the reverse split. The company’s Nasdaq symbol remains LABT and a new CUSIP (51255A201) was assigned.
Lakewood-Amedex Biotherapeutics Inc. filed a prospectus supplement to its Form S-1 incorporating its Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $(923,291) for the three months ended March 31, 2026 and cash and cash equivalents of $11,709 as of that date.
The balance sheet shows total assets of $196,343 and total liabilities of $3,037,991, with shares outstanding of 6,995,469 as of March 31, 2026. Subsequent events disclosed include a private sale of Series C Convertible Preferred Stock that closed on April 21, 2026 for gross proceeds of approximately $7.5M (net proceeds ~$6.8M), the automatic conversion of various convertible instruments upon the company’s Nasdaq listing on April 23, 2026, and the filing of a registration statement covering 9,375,000 common shares issuable upon conversion of the Series C Preferred.
Lakewood-Amedex Biotherapeutics Inc. registers 9,375,000 shares of common stock on a Form S-1 prospectus supplement to cover shares issuable upon conversion of its Series C Convertible Preferred Stock. The prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The Company reported cash and cash equivalents of $11,709 as of March 31, 2026 and a net loss of $923,291 for the three months then ended. The Company completed a private Series C financing that generated gross proceeds of $7.5 million (net proceeds about $6.8 million) in April 2026 and completed its Nasdaq Capital Market listing on April 23, 2026. Management states the net proceeds and debt conversions improve liquidity and are expected to support operations through the fourth quarter of 2026, but notes that substantial doubt about going concern has not been alleviated.
Lakewood-Amedex Biotherapeutics Inc. registers 9,647,726 shares of Common Stock for resale, composed of 9,375,000 shares issuable upon conversion of Series C Preferred Stock and 272,726 shares held by RBW Capital Partners LLC.
The prospectus states the company will receive no proceeds from these resales and that sales may occur at fixed, market, negotiated or other prices through underwriters, brokers, agents, or directly by the selling stockholders. The company paid registration expenses; selling stockholders bear selling commissions and transfer taxes.
Lakewood-Amedex Biotherapeutics appointed Dr. Joseph Tucker to its Board effective April 24, 2026. He will serve until the 2027 annual meeting. The Board agreement requires attendance at two to four meetings per year and reimbursement of pre-approved travel and living expenses.
Dr. Tucker will receive $6,000 per quarter payable in common stock and was granted 33,784 warrants exercisable at $10.00 per share for ten years. The warrants vest in four equal tranches on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028; unvested warrants are cancelled if the Company terminates the agreement.
Lakewood-Amedex Biotherapeutics Inc. filed a prospectus registering the resale of up to 4,689,177 shares of common stock by identified stockholders in connection with a planned direct listing on the Nasdaq Capital Market. The resale is a secondary offering by existing holders; the Company will not receive proceeds from those resale transactions. The company has a binding private placement to sell 937,500 Series C Preferred Shares for aggregate gross proceeds of $7,500,000, convertible into Common Stock under specified pricing terms. The firm engaged RBW Capital Partners as financial advisor; RBW is expected to receive 272,219 advisory shares (1.75% of fully diluted shares) as compensation, which are not registered in this offering. The prospectus discloses recent short-term notes of $125,000 aggregate and summarizes 2025 net loss of $(3,847,637) with cash of $236,400 as of December 31, 2025.